Generic Name and Formulations:
Colchicine 0.6mg; tabs.
Takeda Pharmaceutical Company
Indications for COLCRYS:
Prophylaxis and treatment of acute gout flares. Familial Mediterranean fever (FMF).
Gout prophylaxis: >16yrs: 0.6mg once or twice daily; max 1.2mg/day. Gout treatment: 1.2mg at first sign of gout flare, then 0.6mg 1 hour later; max 1.8mg over a 1 hour period; may be given during prophylaxis at max 1.2mg at first sign of flare, then 0.6mg 1 hour later, wait 12 hours, then resume prophylactic dose. FMF: Usual range: 1.2mg–2.4mg daily; may give in 1–2 divided doses. May increase/decrease dose (depending on tolerability) in increments of 0.3mg/day to max daily dose. For all: concomitant CYP3A4 and/or P-glycoprotein inhibitors, severe renal or hepatic impairment: reduce dose (see literature).
FMF: <4yrs: not recommended. Give as a single or divided dose twice daily. 4–6yrs: 0.3mg–1.8mg daily; 6–12yrs: 0.9mg–1.8mg daily. May increase/decrease dose (depending on tolerability) in increments of 0.3mg/day to max daily dose. Concomitant CYP3A4 and/or P-glycoprotein inhibitors, severe renal or hepatic impairment: reduce dose (see literature).
Renal or hepatic impairment with concomitant strong CYP3A4 or P-glycoprotein inhibitors (life-threatening toxicity possible).
Monitor for toxicity; if present, consider temporary interruption or discontinuation. Renal or hepatic impairment. Elderly. Pregnancy (Cat.C). Nursing mothers.
See Contraindications. Potentiated by concomitant CYP3A4 inhibitors (eg, atazanavir, clarithromycin, indinavir, itraconazole, ketoconazole, nefazodone, nelfinavir, ritonavir, saquinavir, telithromycin, amprenavir, aprepitant, diltiazem, erythromycin, fluconazole, fosamprenavir, verapamil, grapefruit juice) and/or P-glycoprotein inhibitors (eg, cyclosporine, ranolazine). Concomitant statins, gemfibrozil, fibrates, digoxin may potentiate myopathy and rhabdomyolysis.
GI upset, abdominal pain, pharyngolaryngeal pain; blood dyscrasias (myelosuppression, leukopenia, granulocytopenia, thrombocytopenia, pancytopenia, aplastic anemia), neuromuscular toxicity, rhabdomyolysis, overdosage (may be fatal).
Tabs—30, 60, 100, 250, 500, 1000
Sign Up for Free e-newsletters
- Study Finds Association Between Folate Intake and Risk of Cutaneous Melanoma
- Choice of Breast Reconstruction After Mastectomy Affects Satisfaction, Quality of Life
- Carfilzomib Benefits May Outweigh Cardiovascular Risk in Multiple Myeloma
- The Caregivers' Cancer Journey
- Bariatric Surgery Reduced Risk of Some Cancers in Obese Patients
- Implementing an Ambulatory Adherence Program May Improve Oral Anticancer Medications Compliance
- Exercise Habits Influence Mortality in Adult Survivors of Childhood Cancer
- Managing Dyspnea With Fentanyl in Patients With Cancer at End of Life
- CALM: A Depression Intervention for Cancer Patients at the End of Life
- High BMI Among Premenopausal Women May Improve Risk for Breast Cancer
- Fertility Preservation in Hodgkin's Lymphoma Patients That Undergo Targeted Molecular Therapies: An Important Step Forward From the Chemotherapy Era
- Survey of ACEP Councilors Reveals NP, PA Staffing Models, Practice Patterns Vary
- Breath Analysis May Be an Effective Diagnostic for Pancreatic Cancer
- Genetic Susceptibility to Pancreatic Cancer Linked to 6 Specific Gene Mutations
- Dinner Hour and Sleep Habits Affect Risk of Breast, Prostate Cancers
Regimen and Drug Listings
GET FULL LISTINGS OF TREATMENT Regimens and Drug INFORMATION
|Head and Neck Cancer||Regimens||Drugs|